Login to Your Account



Partner Bid Still Alive, CEO Says

Poniard's Picoplatin Phase II: Target Hit, Analysts Skeptical

By Randy Osborne


Tuesday, January 26, 2010
Partnering hopes may have dimmed for Poniard Pharmaceuticals Inc. with the unveiling of Phase II results with picoplatin in metastatic colorectal cancer, news that follows the failure of the chemotherapy agent late last year in a Phase III trial against small-cell lung cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription